Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Imuvert consistently protected against alopecia induced by certain chemotherapy drugs in rats, potentially mediated by a monocyte-derived cytokine like interleukin-1.

In this retrospective cohort study, patients using leflunomide for primary autoimmune conditions showed a decreased risk of developing alopecia areata, while those using methotrexate, cyclosporine, and rituximab had an increased risk.

A heart transplant patient developed a skin condition called epidermodysplasia verruciformis after taking immune-suppressing drugs.

This study reported a series of mild to moderate cutaneous adverse drug reactions following COVID-19 vaccination, predominantly after Covishield, with only one requiring hospitalization.

The researchers designed a Janus microneedle system for treating vitiligo, which targets the skin’s layers to regulate the immune response, promote melanocyte regeneration, and enhance pigment transfer, offering a new precise treatment approach for this condition.

This study found that during the COVID-19 pandemic in China, atopic dermatitis became more prevalent among pediatric skin conditions, while infectious skin diseases decreased, possibly due to mask-wearing.

This abstract provides supplementary materials and directs queries to the corresponding author but presents no new research findings.

This narrative review proposes the concept of "repigmentation competence" for vitiligo lesions, suggesting that therapy responses are influenced by lesion-specific biological factors related to immune, regenerative, regulatory, and microenvironmental processes, and highlights the emerging role of combination therapies targeting these pathways.

In this study, Covishield vaccination was associated with cutaneous adverse effects, notably telogen effluvium and urticaria, among recipients at a hospital in northern India.

This article reviews the potential role of vitamin D supplementation as an adjunct to alemtuzumab therapy in multiple sclerosis management, noting its possible benefits for autoimmune comorbidities and patient adherence, but reports no new clinical results.

This review covers the epidemiology, clinical features, and treatment of four common skin infections in children, reporting no new experimental findings.

This case study describes a 53-year-old woman who developed severe muscle weakness, myalgia, and alopecia after receiving the Pfizer SARS-CoV-2 vaccine, with partial hair regrowth observed after six months.

This study found that prophylactically administering amotosalen-treated allogeneic donor T cells at transplantation significantly improved immune reconstitution and protection against murine cytomegalovirus infection without inducing graft-versus-host disease.

This report discusses a rare case where immune reconstitution inflammatory syndrome in an HIV patient led to dermatologic, ophthalmologic, and neurologic complications due to secondary syphilis.

This article discusses the importance of raising awareness about specific adverse drug reactions, methods of prevention, and the significance of reporting them to the FDA's MedWatch program, but reports no new clinical results.

This study reports that immunologically inert and skewed immune cell populations in developing human skin may contribute to wound healing and structural changes during skin development.

In this study, 2% of healthcare workers vaccinated with Covaxin or Covishield reported new skin reactions, with a slightly higher incidence following Covaxin; significant differences were observed among paramedical staff.

This study found that intralesional Candida antigen was as effective as intralesional steroids for treating alopecia areata after 5 months, with significantly lower injection pain reported in the Candida group.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

In this study, researchers observed six patterns of skin reactions in COVID-19 patients and noted potential skin responses following vaccination, although the mechanisms remain unclear.

In this review, the authors highlighted the potential of natural polysaccharides from plants, animals, and microbes to modulate immune responses, reduce inflammation, and strengthen the intestinal barrier, suggesting their promising role as immunomodulatory agents in pharmaceutical applications.

This article discusses the roles of pediatrics and dermatology departments at Yale University School of Medicine, but reports no specific clinical results.

This review explores advancements in bioprinting technologies for developing in vitro skin models that replicate immune-mediated skin diseases, highlighting their potential to reduce animal testing and enhance research and product testing capabilities in dermatology.

In this case study, a 65-year-old male with hepatocellular carcinoma treated with the PD-1 inhibitor Sintilimab developed alopecia universalis alongside significant tumor regression and complete remission, highlighting a rare immune-related adverse event with effective anti-tumor outcomes.

This report suggests that a severe reaction involving dermatitis, alopecia, and fever in a patient receiving aurothioglucose was likely allergic, as indicated by clinical findings and a positive lymphocyte transformation test.

This case report describes the first known occurrence of alopecia areata associated with cemiplimab, an anti-PD1 drug, in a patient with a positive cancer treatment response.

In this narrative case report, the authors discuss a patient recently diagnosed with an early-stage hematologic malignancy, highlighting her skepticism toward conventional medicine and preference for natural remedies over pharmaceutical treatments.

This study found that patients receiving immune checkpoint inhibitors who have a history of psoriasis are at a higher risk for developing gastrointestinal and endocrine toxicities within one year compared to those without psoriasis.

This study identified numerous drugs with potential to trigger vitiligo, cautioning that these pharmacovigilance findings need further validation and that patients on these medications should be monitored for vitiligo development.

In this original study, researchers documented 121 COVID-19 cases with a wide range of mucocutaneous manifestations, some linked to internal organ damage and others to new vaccine-associated dermatoses, emphasizing the importance of rapid diagnosis to prevent potentially life-threatening systemic events.